Key Points
- Determine whether site-specific polyclonal antibodies can differentiate between two closely adjacent phosphorylation sites (Ser16 and Thr17) on the cardiac protein phospholamban.
- Generated two rabbit polyclonal antibodies, designated PS-16 and PT-17, raised against specific phosphorylated residues of phospholamban.
- Evaluated antibody cross-reactivity and binding specificity against Ser16- and Thr17-phosphorylated phospholamban, dephosphorylated protein, free phosphoamino acids, and other muscle phosphoproteins.
- Antibody PS-16 selectively bound Ser16-phosphorylated phospholamban, whereas PT-17 selectively bound Thr17-phosphorylated phospholamban, showing complete absence of reciprocal cross-reactivity.
- Neither antibody recognized dephosphorylated phospholamban or free phosphoamino acids, maintaining target specificity even in the presence of other muscle phosphoproteins.
Structured PICO
PPopulationRabbits used to produce polyclonal antibodies against phosphorylated forms of the cardiac muscle protein phospholamban
IInterventionPhosphorylation site-specific antibodies (PS-16 and PT-17)
OOutcomeAntibody specificity for Ser16 and Thr17 phosphorylated forms of phospholamban
The development of highly specific antibodies for adjacent phosphorylation sites on phospholamban provides a valuable tool for studying its role in cardiac biology.